XML 78 R69.htm IDEA: XBRL DOCUMENT
v3.24.3

Other financial information - Events after the reporting date (Details) |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 14, 2024 EUR (€) € / shares shares | Oct. 11, 2024 EUR (€) | Jul. 18, 2024 EUR (€) | Jan. 31, 2023 | Jun. 30, 2024 EUR (€) € / shares shares | Dec. 31, 2022 | Jul. 05, 2024 | Dec. 31, 2023 shares | Nov. 28, 2022 shares
Events after the reporting date |  |  |  |  |  |  |  |  |
Par value of share | € / shares |  |  |  |  | € 0.01 |  |  |  |
Finance contract with EIB, first tranche (Tranche A) |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Number of shares per warrant | shares |  |  |  |  | 1.27 |  |  | 1.20 | 1.00
Finance contract with EIB, first tranche (Tranche A) | Warrant agreement with the European Investment Bank |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Number of shares underlying in EIB | shares |  |  |  |  | 1.27 |  |  |  |
Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Maximum duration of Phase III trial |  |  |  | 7 years |  | 840 days |  |  |
Presentation of results from study | NATiV3 Phase III clinical trial |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Percentage of patients in trial, enrolled in main cohort |  |  |  |  |  |  | 80.00% |  |
Percentage of patients in trial, enrolled in exploratory cohort |  |  |  |  |  |  | 100.00% |  |
Issuance of royalty certificates |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Number of royalty certificates issued |  |  | 201 |  |  |  |  |  |
Gross cash proceeds |  |  | € 20,100,000 |  |  |  |  |  |
Annual royalty percentage |  |  | 3.00% |  |  |  |  |  |
Maximum duration of Phase III trial |  |  | 14 years |  |  |  |  |  |
Financing agreement in three phases |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Number of equal tranches |  |  |  |  | 3 |  |  |  |
Aggregate amount to be received either in exchange for new shares or warrants |  |  |  |  | € 348,000,000 |  |  |  |
Issuance of shares without preferential subscription rights |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Stock issued during period | € 94,100,000 |  |  |  |  |  |  |  |
Number of shares issued during the period | shares | 34,600,507 |  |  |  |  |  |  |  |
Par value of share | € / shares | € 0.01 |  |  |  |  |  |  |  |
Number of warrants granted | shares | 35,399,481 |  |  |  |  |  |  |  |
Number of shares per warrant | shares | 1 |  |  |  |  |  |  |  |
Issuance of shares or warrants without preferential subscription rights |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Stock issued during period | € 21,400,000 |  |  |  |  |  |  |  |
Par value of share | € / shares | € 0.01 |  |  |  |  |  |  |  |
Issuance of shares or warrants subject to conditions |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Stock issued during period | € 116,000,000 |  |  |  |  |  |  |  |
Exercise price of warrant | € / shares | € 1.50 |  |  |  |  |  |  |  |
Class of warrant or right, value of number of securities | € 116,000,000 |  |  |  |  |  |  |  |
Financing through fund raising | Licensing and collaboration agreement with CTTQ |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Minimum amount committed for fund raising |  | € 180,000,000 |  |  |  |  |  |  |
Financing through fund raising | Licensing and collaboration agreement with CTTQ | First tranche |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Amount received on licensing arrangements |  | € 10,000,000 |  |  |  |  |  |  |
Received from settlement |  | 30 days |  |  |  |  |  |  |
Financing through fund raising | Licensing and collaboration agreement with CTTQ | Second tranche |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Amount received on licensing arrangements |  | € 10,000,000 |  |  |  |  |  |  |
Financing through fund raising | Licensing and collaboration agreement with CTTQ | Third tranche upon publication of pivotal data |  |  |  |  |  |  |  |  |
Events after the reporting date |  |  |  |  |  |  |  |  |
Amount received on licensing arrangements |  | € 10,000,000 |  |  |  |  |  |  |

X
- Definition The nominal value per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 79 -Subparagraph a -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ParValuePerShare
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company. + References No definition available. + Details
Name: | iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of annual royalty on future net sales of Lanifibranor. + References No definition available. + Details
Name: | iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of warrants or rights granted. + References No definition available. + Details
Name: | iva_ClassOfWarrantOrRightGranted
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References No definition available. + Details
Name: | iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
Namespace Prefix: | iva_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References No definition available. + Details
Name: | iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of securities into which the class of warrant or right may be converted. + References No definition available. + Details
Name: | iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | iva_IfrsotherFinancialInformationLineItems
Namespace Prefix: | iva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum duration of the clinical trial of the entity. + References No definition available. + Details
Name: | iva_MaximumDurationOfClinicalTrial
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The minimum amount committed for borrowing under the agreement. + References No definition available. + Details
Name: | iva_MinimumAmountCommittedForFundRaising
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represent the information of number of equal tranches . + References No definition available. + Details
Name: | iva_NumberOfEqualTranches
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of royalty certificates issued. + References No definition available. + Details
Name: | iva_NumberOfRoyaltyCertificatesIssued
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of patients in trail enrolled in exploratory cohort. + References No definition available. + Details
Name: | iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of patients in trail enrolled in main cohort. + References No definition available. + Details
Name: | iva_PercentageOfPatientsInTrialEnrolledInMainCohort
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The period within which the payment is made from settlement date. + References No definition available. + Details
Name: | iva_PeriodWithinWhichPaymentIsReceivedFromSettlement
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash proceeds from financing. + References No definition available. + Details
Name: | iva_ProceedsFromFinancing
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount paid on licensing arrangements. + References No definition available. + Details
Name: | iva_ProceedsFromLicensingArrangements
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued during the period. + References No definition available. + Details
Name: | iva_StockIssuedDuringPeriodShares
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References No definition available. + Details
Name: | iva_StockIssuedDuringPeriodValue
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_PresentationOfResultsFromStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfRoyaltyCertificatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingAgreementInThreePhasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingThroughFundRaisingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=iva_ScenarioOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=iva_ScenarioTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=iva_ScenarioThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |